TY - JOUR
TI - Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis
AU - Fermeli, D.D.
AU - Marantos, T.D.
AU - Liarakos, A.-L.D.
AU - Panayiotakopoulos, G.D.
AU - Dedes, V.K.
AU - Panoutsopoulos, G.I.
JO - Folia Medica
PY - 2020
VL - 62
TODO - 3
SP - 444-452
PB - NLM (Medline)
SN - 0204-8043
TODO - 10.3897/folmed.62.e48742
TODO - linezolid;  tuberculostatic agent, drug effect;  extensively drug resistant tuberculosis;  human;  microbiology;  Mycobacterium tuberculosis, Antitubercular Agents;  Extensively Drug-Resistant Tuberculosis;  Humans;  Linezolid;  Mycobacterium tuberculosis
TODO - Tuberculosis is a severe, infectious disease caused by Mycobacterium tuberculosis. The aim of this review was to present the efficacy of linezolid as an agent against multidrug and extensively drug-resistant tuberculosis as gathered from many recent research studies. Linezolid seems to have strongly the potential of being used as an anti-tuberculosis agent because it blocks bacterial ribosomal protein synthesis. Nevertheless caution is required because of the adverse effects it causes, especially when the linezolid daily dosage exceeds 600 mg. The most severe adverse effects include anemia, peripheral neuropathy, optic neuropathy and thrombocytopenia. Still, more trials and research need to be done in order to gather more information and value the cost-benefit dosage of the treatment. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ER -